JCJan Ciszewski

Jan Ciszewski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jan Ciszewski has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Mariusz Pytkowski

    2nd Department of Cardiac Arrhythmia, National Institute of Cardiology, Warszawa, Poland

    4 shared publications
  • Agnieszka Jankowska

    Outpatient Cardiology Clinic, National Institute of Cardiology, Warszawa, Poland

    3 shared publications
  • Aleksander Maciąg

    2nd Department of Cardiac Arrhythmia, National Institute of Cardiology, Warszawa, Poland

    3 shared publications
  • Ilona Kowalik

    Clinical Research Support Center, National Institute of Cardiology, Warszawa, Poland

    3 shared publications
  • Maciej Sterliński

    1st Department of Cardiac Arrhythmia, National Institute of Cardiology, Warszawa, Poland

    3 shared publications
  • Anna Borowiec

    Instytut Kardiologii im. Prymasa Tysiąclecia Stefana Kardynała Wyszyńskiego

    2 shared publications

Latest Publications

  • The effect of short-term amiodarone treatment on the effectiveness of catheter ablation in patients with persistent atrial fibrillation refractory to cardioversion

    by Mariusz Pytkowski, Jan Ciszewski, Grzegorz Erhenhalt, Michał M Farkowski, Rafał Baranowski, Hanna Rymuza, Barbara Jędrzejczyk, Agnieszka Jankowska, Ilona Kowalik, Paweł Syska, et al.

    Little is known about the effect of amiodarone therapy in patients with persistent atrial fibrillation refractory to electrical cardioversion (AF-REC) scheduled for catheter ablation (CA). This study aimed to determine whether postulated atrial reverse remodelling achieved through short-term pre- and post-ablation amiodarone therapy with sinus rhythm restoration prior to CA affects the long-term effectiveness of the rhythm control strategy in AF-REC patients. AF-REC patients scheduled for CA were included in this retrospective study. In those patients who received amiodarone (Group A) sinus rhythm was restored before CA. In patients without amiodarone (Group NA) sinus rhythm was restored at the end of CA. Results of outpatient visits, 72-hour electrocardiography Holter, echocardiography and perceived symptoms were assessed in follow-up. Study population consisted of 56 patients: 37 from Group A and 19 Group NA; median follow-up 39.5 months. The primary endpoint (AF-free survival) was achieved in 17 (45.9%) patients in group A and in 3 (15.8%) patients in group NA (P = 0.026). Secondary endpoint: conversion of AF from persistent to paroxysmal or no AF was achieved in 32 patients (86.5%) from Group A and 9 patients (47.4%) from Group NA: odds ratio 8.0 (95% confidence interval, 2.1-30.0); P = 0.002. Age adjusted left ventricular ejection fraction improvement was greater in group A in comparison to Group NA, P = 0.004. Patient's symptoms (European Heart Rhythm Association scale) improved in both groups A ad NA; P <0.001. Short term amiodarone combined with sinus rhythm restoration prior to AF ablation in AF-REC patients may improve long-term treatment effects.


  • Open Access

    Rhythm and rate control strategies in patients with long-standing persistent atrial fibrillation treated with cardiac resynchronization: the results of the randomized Pilot-CRAfT study

    by Jan B. Ciszewski, Mateusz Tajstra, Ilona Kowalik, Aleksander Maciąg, Tomasz Chwyczko, Agnieszka Jankowska, Edyta Smolis-Bąk, Bohdan Firek, Dariusz Zając, Jarosław Karwowski, et al.

    Background: Atrial fibrillation (AF) is common in cardiac resynchronization therapy (CRT) recipients. It is a marker of impaired CRT response mainly mediated by the reduction of effectively captured biventricular paced beats (BiVp). There are no randomized trials comparing strategies to maintain high BiVp percentage. Objective: To compare the efficacy of rhythm vs rate control strategies in CRT recipients with long-standing persistent AF. Methods: We performed a randomized trial including CRT recipients with persistent AF resulting in low BiVp%. All patients received amiodarone, the rhythm control group received external electrical cardioversion (EC), and the rate control group received atrioventricular node ablation, if needed. The primary end-point was 12-month BiVp% (NCT). Results: 43 patients were included in the analysis. The mean age was 68.4 (SD: ± 8.3) years and the mean BiVp% 82.4% ± 9.7%. AF lasted 25 ± 19 months. The mean baseline left ventricular ejection fraction (LVEF), left atrium area, and the maximal oxygen uptake (VO2max) were: 30 ± 8%, 33 ± 7 cm 2 , and 14 ± 5 mL/(kg*min), respectively. The EC success rate was 58%. 38% patients remained in sinus rhythm (SR) after 12 months. BiVp% increased similarly in both arms reaching 99% [95% CI 97.3–99.8] and 98% [94.0–99.0], P = 0.14 in rhythm and rate control groups, respectively. LVEF raised significantly only in the rhythm control group (ΔLVEF 4.1 (± 7.3), P = 0,018) which was driven by the patients who maintained SR. No differences in VO2max, QoL, clinical and safety end-points were observed. Conclusion: Despite comparable BiVp% in both groups, only restoration of SR led to improved left ventricular ejection fraction in CRT patients with long-standing AF. Trial registration: NCT01850277 registered on 22/04/2013.


  • Open Access

    The effect of amiodarone given periprocedurally on the effectiveness of catheter ablation in patients with persistent atrial fibrillation refractory to cardioversion

    by G Ehrenhalt, J Ciszewski, M Farkowski, R Baranowski, H Rymuza, B Jedrzejczyk, A Jankowska, I Kowalik, A Maciag, P Syska, et al.

    Background: Rhythm control strategy in patients with persistent atrial fibrillation refractory to electrical cardioversion (AF-REC) poses an important clinical problem. Little is known about the effect of amiodarone therapy given periprocedurally with catheter ablation on maintaining sinus rhythm in this group of patients. Purpose: This study aimed to determine whether initial amiodarone therapy introduced prior to AF ablation and continued for one month after the procedure affects the long-term effectiveness of the rhythm control strategy in patients with AF-REC. Methods: We conducted a retrospective case-control study of medical records of AF-REC patients treated periprocedurally with amiodarone in addition to pulmonary vein isolation. Data on comorbidities, transthoracic echocardiogram results, and short- and long-term effectiveness of ablation was extracted. Patients were followed up in the out patient clinic with the use of a 72-hour Holter monitoring and telephone interviews. AF recurrence was defined as ≥ 30s episode of atrial tachyarrhythmia. Results: The analysis comprised 56 patients: 37 in the amiodarone and 19 in the control group; 12 women, mean age 57 years, mean follow-up of 39.5 months. Amiodarone was discontinued after 1 month at the most after the ablation in all of the patients. The primary endpoint (AF-free survival) was achieved in 17 (45,9%) pts in the amiodarone group and 3 (15,8%) pts in the control group (p=0.026). On multivariable analysis, amiodarone therapy was the only variable correlating with the primary endpoint: OR 6.8 (95% CI: 1.4 - 33.9), p=0.019. Conversion of AF from persistent to paroxysmal or no AF in the follow-up was achieved in 32 pts (86,5%) in the amiodarone group and 9 pts (47,4%) in the control group: OR 8.0 (95% CI: 2.1 - 30.0), p=0.002. Patients in the amiodarone group experienced a borderline better increase of left ventricular ejection fraction: ∆ 5.2% (95% CI: -0.1 - 10.5), p= 0.054. Conclusion: Periprocedural use of amiodarone in patients ablated due to persistent atrial fibrillation refractory to electrical cardioversion may lead to significantly better long-term efficacy of catheter ablation in this group of patients.

  • Open Access

    Management of Atrial Fibrillation in Recipients of Cardiac Resynchronization Therapy

    by Jan Ciszewski, Maciej Sterliński

    Atrial fibrillation (AF) and heart failure (HF) often co-exist. The incidence of AF is estimated to reach 45% of patients with HF and rises with the severity

  • An unexpected outcome of successful radiofrequency ablation for persistent typical atrial flutter lasting 12 years

    by Jan B. Ciszewski, Michał M. Farkowski, Dariusz Zając, Aleksander Maciąg, Mariusz A. Dębski, Marcin Demkow, Mariusz Pytkowski

    DOI: 10.33963/KP.15296, Published online: April 15, 2020, Authors: Jan B. Ciszewski, Michał M. Farkowski, Dariusz Zając, Aleksander Maciąg, Mariusz A. Dębski, Marcin Demkow, Mariusz Pytkowski

  • Clinical, echocardiographic, and pacing parameters affecting atrial fibrillation burden in patients with tachycardia-bradycardia syndrome

    by Jan Bohdan Ciszewski, Tomasz Chwyczko, Ilona Kowalik, Wojciech Majda, Michał Mirosław Farkowski, Agnieszka Jankowska, Anna Borowiec, Paweł Syska, Hanna Szwed, Mariusz Pytkowski

    Background: The influence of different factors on the atrial fibrillation (AF) development in the population of tachycardia bradycardia syndrome (TBS) patients remains unclear. There is no data examining such an impact of different right ventricular pacing percentage (RVp%) profiles. Aim: The purpose of the study was to evaluate the relationship between the AF burden (AFB) and different clinical, echocardiographic and pacing parameters in TBS patients. Methods: We performed a prospective, one-year registry of TBS patients with documented AF referred to the dual-chamber pacemaker (DDD) implantation. Results: The data of 65 patients were analyzed. The median 12 month RVp% and AFB was 9.4% and 1.0%, respectively. During the follow-up 14% of patients had no AF (P=0.003) and the withdrawal of AF symptoms was observed in 49% of patients (Pr=0.31, P=0.02), especially in the subjects with the left ventricular ejection fraction 20% subgroup there was an significant increase of AFB in comparison to the RVp% ≤ 20% subgroup (ΔAFB 1.8% vs 0.0%, p=0.03, respectively). In the increasing RVp% group (n=28) the AFB increased whereas in the decreasing RVp% (n=16) it remained stable (ΔAFB 0.67% vs 0.0%, p=0.034, respectively). Conclusions: The DDD implantation in TBS patients is related to a significant AF symptoms reduction and LA diameter correlates with cumulative AFB in the mid-term observation. Stable RVp% >20% is associated with AF progression whereas lower stable RVp% may stabilize AF development. Increasing RVp% may be connected to the AFB increase in comparison to the decreasing RVp% subgroup in which AFB remains stable. Background: The influence of different factors on the atrial fibrillation (AF) development in the population of tachycardia bradycardia syndrome (TBS) patients remains unclear. There is no data examining such an impact of different right ventricular pacing percentage (RVp%) profiles. Aim: The purpose of the study was to evaluate the relationship between the AF burden (AFB) and different clinical, echocardiographic and pacing parameters in TBS patients. Methods: We performed a prospective, one-year registry of TBS patients with documented AF referred to the dual-chamber pacemaker (DDD) implantation. Results: The data of 65 patients were analyzed. The median 12 month RVp% and AFB was 9.4% and 1.0%, respectively. During the follow-up 14% of patients had no AF (P=0.003) and the withdrawal of AF symptoms was observed in 49% of patients (Pr=0.31, P=0.02), especially in the subjects with the left ventricular ejection fraction 20% subgroup there was an significant increase of AFB in comparison to the RVp% ≤ 20% subgroup (ΔAFB 1.8% vs 0.0%, p=0.03, respectively). In the increasing RVp% group (n=28) the AFB increased whereas in the decreasing RVp% (n=16) it remained stable (ΔAFB 0.67% vs 0.0%, p=0.034, respectively). Conclusions: The DDD implantation in TBS patients is related to a significant AF symptoms reduction and LA diameter correlates with cumulative AFB in the mid-term observation. Stable RVp% >20% is associated with AF progression whereas lower stable RVp% may stabilize AF development. Increasing RVp% may be connected to the AFB increase in comparison to the decreasing RVp% subgroup in which AFB remains stable.


  • Open Access

    Comparison of the rhythm control treatment strategy versus the rate control strategy in patients with permanent or long-standing persistent atrial fibrillation and heart failure treated with cardiac resynchronization therapy - a pilot study of Cardiac Resynchronization in Atrial Fibrillation Trial (Pilot-CRAfT): study protocol for a randomized controlled trial

    by Jan Ciszewski, Aleksander Maciag, Ilona Kowalik, Pawel Syska, Michal Lewandowski, Michal M Farkowski, Anna Borowiec, Tomasz Chwyczko, Mariusz Pytkowski, Hanna Szwed, et al.

    The only subgroups of patients with heart failure and atrial fibrillation in which the efficacy of cardiac resynchronization therapy has been scientifically proven are patients with indications for right ventricular pacing and patients after atrioventricular junction ablation. However it is unlikely that atrioventricular junction ablation would be a standard procedure in the majority of the heart failure patients with cardiac resynchronization therapy and concomitant atrial fibrillation due to the irreversible character of the procedure and a spontaneous sinus rhythm resumption that occurs in about 10% of these patients. Pilot-CRAfT is the first randomized controlled trial evaluating the efficacy of a rhythm control strategy in atrial fibrillation patients with cardiac resynchronization therapy devices. The aim of this prospective, single center randomized controlled pilot study is to answer the question whether the patients with cardiac resynchronization therapy and permanent atrial fibrillation would benefit from a strategy to restore and maintain sinus rhythm (that is ‘rhythm control’ strategy) in comparison to rate control strategy. The study population consists of 60 patients with heart failure and concomitant long-standing persistent or permanent atrial fibrillation who underwent a cardiac resynchronization therapy device implantation at least 3 months before qualification. Study participants are randomly assigned to the rhythm control strategy (including electrical cardioversion and pharmacotherapy) or to the rate control group whose goal is to control ventricular rate. The follow-up time is 12 months. The primary endpoint is the ratio of effectively captured biventricular beats. The secondary endpoints include peak oxygen consumption, six-minute walk test distance, heart failure symptom escalation, reverse remodelling of the heart on echo and quality of life. NCT01850277 registered on 22 April 2013 (ClinicalTrails.gov)